title: Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis.
abstract: Potent antiretroviral therapy stimulates robust and durable immune reconstitution among profoundly immunosuppressed patients that is clinically important. Fifteen patients with cytomegalovirus retinitis (CMVR) were followed after discontinuing anti-cytomegalovirus therapy. No patients had progression or relapse for a median of 51 months. Survival from the diagnosis of CMVR was universal for up to 95 months, with an observation period averaging more than 6 years. The CD4 cell count continued to rise through the fourth year of follow-up.
authors.affiliation: The Critical Care Medicine Department, Clinical Center, National Institute of Allergy and Infectious Diseases, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Sklar
authors.forename: Amma F
authors.initials: AF
authors.lastname: Agyemang
authors.forename: Rachelle
authors.initials: R
authors.lastname: Monastra
authors.forename: Diane Rock
authors.initials: DR
authors.lastname: Kress
authors.forename: Julia A
authors.initials: JA
authors.lastname: Metcalf
authors.forename: Michael R
authors.initials: MR
authors.lastname: Robinson
authors.forename: Henry
authors.initials: H
authors.lastname: Masur
authors.forename: Michael A
authors.initials: MA
authors.lastname: Polis
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy / Q000276:immunology*; D005500:Follow-Up Studies; D006801:Humans; D007108:Immune Tolerance